Apple Pectin May Fight Colitis, Cancer

April 23, 2010

1 Min Read
Apple Pectin May Fight Colitis, Cancer

SHAANXI, Peoples Republic of ChinaResearchers have long thought inflammation was linked to cancer; and colitis, inflammation of the colon, increases the developmental risk of colon cancer. In a recent Chinese study published in Carcinogenesis, researchers obtained an oligogalactan composed of five galacturonic acids from apple pectin and evaluated its protective efficacy on intestinal toxicities and carcinogenesis in a mouse model of colitis-associated colon cancer induced by 1, 2-dimethyl-hydrazine (DMH) and dextran sodium sulfate (DSS) (April 16, 2010).

The apple oligogalactan (AOG) was highly effective against intestinal toxicities and carcinogenesis and decreased the elevated levels of toll-like receptor4 (TLR4) and TNF-induced by inflammation in vivo. In vitro studies, AOG alone only slightly increased the levels of protein expression and mRNA of TLR4, phosphorylation of IB, and production of TNF- in HT-29 cells. However, AOG significantly decreased the elevation of all the biomarkers induced by lipopolysaccharide (LPS) when it was combined with LPS.

Researchers said: The effect of AOG may be related to membrane internalization and redistribution of TLR4 from cell membrane to cytoplasm. AOG is active against inflammation and carcinogenesis through targeting LPS/TLR4/NF-B pathway. Both AOG and LPS are agonists of TLR4 for sharing the same ligand, but AOG has a much lower intrinsic activity than that of LPS. AOG may be useful for treatment of colitis and prevention of carcinogenesis in the clinics.



Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like